ADAR1 Capital Management’s Madrigal Pharmaceuticals MDGL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$481K Hold
895
0.02% 213
2026
Q1
$469K Hold
895
0.03% 208
2025
Q4
$521K Sell
895
-4,000
-82% -$2.04M 0.04% 180
2025
Q3
$2.25M Buy
4,895
+3,841
+364% +$1.43M 0.21% 73
2025
Q2
$319K Sell
1,054
-436
-29% -$130K 0.05% 135
2025
Q1
$494K Buy
+1,490
New +$490K 0.09% 105
2024
Q4
Sell
-50
Closed -$10.6K 268
2024
Q3
$10.6K Buy
+50
New +$12.8K ﹤0.01% 253

Other funds holding MDGL

ADAR1 Capital Management's MDGL Position: Q2 2026 in Review

ADAR1 Capital Management held its Madrigal Pharmaceuticals (MDGL) position steady in Q2 2026 at 895 shares worth $481K. The position accounts for 0.02% of the portfolio, ranked #213.

ADAR1 Capital Management first reported a position in MDGL in Q3 2024 and has held it in 7 quarters since. The position peaked at $2.25M in Q3 2025. 413 funds tracked by Wall St. Rank hold MDGL as of Q2 2026.

  • ADAR1 Capital Management held 895 shares of Madrigal Pharmaceuticals worth $481K as of Q2 2026.
  • ADAR1 Capital Management left its Madrigal Pharmaceuticals share count unchanged in Q2 2026.
  • Madrigal Pharmaceuticals made up 0.02% of ADAR1 Capital Management's portfolio in Q2 2026, its #213 holding.
  • ADAR1 Capital Management first reported a position in Madrigal Pharmaceuticals in Q3 2024 and has held it in 7 quarters since.
  • ADAR1 Capital Management's Madrigal Pharmaceuticals position peaked at $2.25M in Q3 2025.
  • 413 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2026.

Based on ADAR1 Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.